Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

United Therapeutics (UTHR) is highlighted as a potential value stock, despite holding a Zacks #3 (Hold) Rank, due to its top-tier 'A' ratings for both its Value and overall VGM Style Scores. This assessment is underpinned by an attractive forward P/E of 10.52 and recent upward revisions to its FY2025 earnings estimates by analysts, with the Zacks Consensus Estimate increasing to $27.19 per share. The combination of strong Style Scores and positive earnings revisions suggests UTHR warrants consideration for investors seeking value opportunities.

Analysis

United Therapeutics (UTHR) presents a compelling value proposition despite its neutral Zacks #3 'Hold' rating, primarily driven by strong underlying quantitative metrics. The company scores an 'A' for both its overall VGM (Value, Growth, Momentum) and its specific Value Style Score, underscoring its appeal to value-focused investors. This is substantiated by an attractive forward price-to-earnings (P/E) ratio of 10.52. Furthermore, the forward-looking outlook appears to be improving, as evidenced by three analysts revising their fiscal 2025 earnings estimates upward within the last 60 days. This has lifted the Zacks Consensus Estimate for fiscal 2025 by $0.16 to $27.19 per share. While its average earnings surprise of 0.7% is modest, it points to a consistent record of meeting or slightly beating expectations. The combination of a low valuation multiple and positive earnings estimate revisions suggests that the stock's fundamental outlook may be stronger than its 'Hold' rank currently implies.

Key Decisions for Investors

• Value-oriented investors should consider UTHR's attractive valuation, highlighted by its forward P/E of 10.52 and 'A' grade for Value, as a potential entry point for an undervalued biotech name.
• Monitor for any potential upgrade to the Zacks Rank from its current #3 (Hold) status, as the positive earnings revisions for FY2025 could serve as a leading indicator for a future ratings improvement and act as a stock catalyst.
• Investors should pay close attention to subsequent analyst earnings estimate revisions, as continued upward momentum in the consensus forecast is crucial for validating the long-term value thesis presented.